Daiichi Sankyo Cancer Enterprise

Daiichi-Sankyo cancerenterprise

The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.

World-Class Science Organization

The Daiichi Sankyo Cancer Enterprise is committed to becoming a world-class science organization. Our team's exceptional scientific attitude results in outstanding medicinal chemistry, antibody engineering and discovery biology.

Dynamic and Sustainable R&D Engine

The Daiichi Sankyo Cancer Enterprise portfolio is powered by our research engines:

- Two laboratories for biologic/immuno-oncology and small molecules in Japan.
- Plexxikon Inc. – small molecule structure-guided R&D center in Berkeley, California.

7 New Molecular Entities by 2025

Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science Franchise, the Daiichi Sankyo Cancer Enterprise aims to deliver seven distinct new molecular entities over eight years during 2018 to 2025.

Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritization:

Research & Technology

zymeworks · Darwin Health · sysmex · Glycotope Biotechnology · 国立がん研究センター National Cancer Center Japan · JVC KENWOOD · Max-Planck-Innovation · Lead Discovery Center LDC

Translational & Development

AgonOx · Bristol-Myers Squibb · Dana-Farber Cancer Institute · Memorial Sloan Kettering Cancer Center · Kite A Gilead Company · The University of Texas MD Anderson Cancer Center · Puma Biotechnology

Pipeline at a Glance

Daiichi-Sankyo cancerenterprise

Care. Compassion. Science. It's Our Obligation.

We aim to deliver seven distinct new molecular entities in eight years during 2018 to 2025.

These are investigational agents and have not been approved by the FDA or any other regulatory agency worldwide as a treatment for any indication. Safety and efficacy have not been established.

Antibody Drug Conjugate (ADC) Franchise

COMPOUND	TUMOR TYPE	TUMOR EXPRESSING	PHASE OF DEVELOPMENT (REGION)
DS-8201	Breast Cancer (DESTINY-Breast01) *FDA Breakthrough Therapy Designation* *FDA Fast Track Designation*	HER2	Phase 2 (US, EU, Japan)
	Gastric Cancer (DESTINY-Gastric01)		Phase 2 (Japan, Asia)
	Colorectal Cancer		Phase 2 preparation (US, EU, Japan)
	Solid Tumors		Phase 1 (US, Japan)
DS-8201 [in combination with nivolumab]	Breast Cancer, Bladder Cancer	HER2	Phase 1 preparation (US, EU)
U3-1402	Breast Cancer	HER3	Phase 1 (Japan, US)
	Non-Small Cell Lung Cancer		Phase 1 (US, EU)
DS-1062	Non-Small Cell Lung Cancer	TROP2	Phase 1 (US, Japan)
DS-7300	Solid Tumors	B7-H3	Preclinical
DS-6157	Gastrointestinal Stromal Tumor (GIST)	Undisclosed	Preclinical
DS-6000	Renal Cancer, Ovarian Cancer	Undisclosed	Preclinical

Acute Myeloid Leukemia (AML) Franchise

COMPOUND	TUMOR TYPE	RELEVANT PATHWAY (CLASS OF TARGET)	PHASE OF DEVELOPMENT (REGION)
Quizartinib (AC220)	Newly-Diagnosed AML (QuANTUM-First)	FLT3 (growth factor receptor inhibition)	Phase 3 (US, EU, Asia)
	Relapsed/Refractory AML (QuANTUM-R) *FDA Fast Track Designation* *Orphan Drug Designation*		Phase 3 (US, EU, Asia)
	Relapsed/Refractory AML		Phase 2 (Japan)
Quizartinib + DS-3032	Relapsed/Refractory AML Newly-Diagnosed AML	FLT3 (growth factor receptor inhibition) MDM2 (reactivation of p53 tumor suppressor)	Phase 1 preparation (US)
DS-3032	AML, Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome (MDS)	MDM2 (reactivation of p53 tumor suppressor)	Phase 1 (US)
	Solid Tumors, Lymphoma		Phase 1 (US)
	Solid Tumors, Lymphoma		Phase 1 (Japan)
DS-3201	AML, ALL	EZH1/2 (epigenetic regulation)	Phase 1 (US)
	Non-Hodgkin's Lymphoma		Phase 1 (Japan)
PLX51107	AML, MDS, Lymphoma, Solid Tumors	BRD4 (epigenetic regulation)	Phase 1 (US)
DS-1001	AML	IDH1 (epigenetic regulation)	Preclinical

Breakthrough Science Franchise

COMPOUND	TUMOR TYPE	RELEVANT PATHWAY	PHASE OF DEVELOPMENT (REGION)
Pexidartinib (PLX3397)	TGCT (ENLIVEN) *FDA Breakthrough Therapy Designation* *Orphan Drug Designation*	CSF-1R	Phase 3 (US, EU)
Patritumab (U3-1287)	Head and Neck Cancer	HER3	Phase 2 (EU)
DS-1205 [in combination with osimertinib]	Non-Small Cell Lung Cancer	AXL	Phase 1 preparation (US)
DS-1647	Glioblastoma *SAKIGAKE Designation*	Oncolytic HSV-1	Phase 2 (Japan)
DS-1001	Gliomas	IDH1	Phase 1 (Japan)
PLX2853	Solid Tumors	BRD4	Phase 1 (US)
PLX73086	TGCT	CSF-1R	Phase 1 (US)
PLX7486	Solid Tumors	FMS/TRK	Phase 1 (US)
PLX8394	Solid Tumors	BRAF	Phase 1 (US)
PLX9486	Solid Tumors	KIT	Phase 1 (US)